ERBB2 and breast carcinoma: HER2 low-expressing tumors may be more sensitive to different growth factors that stimulate breast cancer cells, as HER2 signaling is a key factor in breast cancer proliferation (22).In addition, the prognosis of lymph node-negative patients is usually better than lymph node-positive patients.